Drugs / BVD-523
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02994732 | Jan → Feb 2017 | — | BioMed Valley Discoveries, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02608229 | Jun 2016 → Mar 2019 | malignant pancreatic neoplasm | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02296242 | Nov 2014 → Jun 2017 | acute myeloid leukemia, myelodysplastic syndrome | BioMed Valley Discoveries, Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT01781429 | Mar 2013 → Feb 2018 | cancer | BioMed Valley Discoveries, Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03417739 | Mar 2018 → May 2020 | uveal melanoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BVD-523 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02994732 ↗ |
| Known as | ulixertinib | “Here we report the discovery of BVD-523 (ulixertinib), a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity.” PMID 28939558 ↗ Sep 2017 |
| Action | Inhibit | “Here we report the discovery of BVD-523 (ulixertinib), a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity.” PMID 28939558 ↗ Sep 2017 |
| Modality | Small molecule | “Here we report the discovery of BVD-523 (ulixertinib), a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity.” PMID 28939558 ↗ Sep 2017 |
| Route | Oral | “Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle” NCT01781429 ↗ |